Rochester, Mich. – September 20, 2026 -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) at the hospital level after detecting particulate matter identified as cellulose or stopper material.

Indianapolis – September 20, 2026 -- The U.S. Food and Drug Administration has granted full approval to Eli Lilly and Company's (NYSE: LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.

Huntersville, N.C. – September 20, 2026 -- BioCytics, Inc. has engaged Eremid Genomic Services to perform single cell transcriptomic and TCR sequencing analysis on immune cells central to its autologous cancer cell therapy program.

Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.

Columbus, Ohio – September 20, 2026 -- Andelyn Biosciences has begun commercial manufacturing of FAYUVI (rebisufligene etisparvovec-hopf) at its Columbus facility, marking the first FDA-approved gene therapy produced using the company's AAV Curator Platform process. The therapy, developed by Ultragenyx Pharmaceutical Inc., recently received U.S. Food and Drug Administration approval for treating Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA).

Taipei – September 19, 2026 -- The 2026 Tang Prize Award Ceremony convened in Taipei on September 18, honoring six laureates across four categories including three scientists whose work led to FDA-approved CAR T-cell cancer therapies now used worldwide.

Madrid – September 19, 2026 -- mAbxience and Sandoz have signed a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar targeting hemophilia A, a treatment referencing Roche's Hemlibra with an estimated global reference market of USD 5.7 billion.

Zurich – September 19, 2026 -- ACROBiosystems has established a dedicated office within The HIVE Innovation Center on Campus Grand Parc in Villejuif, deepening its footprint in France's oncology research corridor. The move, facilitated by real estate operator Kadans Science Partner, gives the roughly 1,000-employee biotechnology group direct proximity to biotechs, hospitals, and translational research institutes clustered around Paris-Saclay.

San Diego – September 19, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) priced $1.3 billion in convertible senior notes due 2033, upsized from an initially announced $1.05 billion offering, carrying a 1.50% annual coupon.

Austin, Texas – – September 19, 2026 -- Otsuka ICU Medical LLC has issued a voluntary user-level recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL, after discovering that bags labeled as saline may actually contain highly concentrated Potassium Chloride Injection.